Business
Investor Webinar
Investor Webinar.
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n \n \nInvestor Webinar\n \n \nLONDON and PHILADELPHIA - May 12, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that Dr Christina Coughlin, Chief Executive Officer, and Michelle Morrow, Chief Scientific Officer, will be presenting at a webinar on 15 May 2025 at 6.00 pm (BST).\nThe webinar is open to all existing and potential investors and will focus on the Company's recent data presentations on its proprietary pre|CISION® candidates FAP-Dox (AVA6000) and FAP-EXd (AVA6103) at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA.\nThe Company welcomes investor interaction so there will be a Q&A session after the presentation and questions can be submitted pre-event as part of the registration process. The webinar will be hosted by Turner Pope Investments.\nInvestors can register for the event by using the following link:\nhttps://www.turnerpope.com/register/ \n \n \n-Ends-\n \nFor further information from Avacta, please contact:\n \n\n\n\n\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\n\n\nhttps://avacta.com/\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\n \n \n\n\n \nwww.peelhunt.com\n \n\n\n\n\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\n \n\n\nwww.panmureliberum.com\n\n\n\n\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\n\n\n \[email protected]\n \n\n\n\n\n \nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\n \n\n\n \n \[email protected]\n \n\n\n\n\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\n\n\n \[email protected] \n\n\n\n\n \n \nAbout Avacta - https://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor micro...